Dmt Safety Issues | Ean 2020 Summary By Multiple Sclerosis Academy

DMT safety issues | EAN 2020 summary by Multiple Sclerosis Academy

Neurology Academy

Starting & switching DMTs | EAN 2020 summary by Multiple Sclerosis Academy

Neurology Academy

Progressive MS | EAN 2020 summary by Multiple Sclerosis Academy

Neurology Academy

Progressive MS & Starting and switching DMTs – part 2 | EAN 2020 summary by MS Academy

Neurology Academy

EAN 2020: Introduction and reflections on a virtual congress | Multiple Sclerosis Academy

Neurology Academy

Harnessing the Full Potential of DMT Mechanisms of Action to Improve MS Outcomes

Prof Gavin Giovannoni: Managing MS remotely during the COVID-19 pandemic

Neurology Academy

Early Initiation of DMTs in MS

Formalising remote management of multiple sclerosis | MS Academy #MSCovid19

Neurology Academy

Bianca Weinstock-Guttman, EAN 2020 – CHORDS Study in RRMS With Suboptimal Prior Response to DMTs

Touch Medical Media

When to make a timely switch to high-efficacy DMT for MS

A Clinician's Guide to Cognition in MS: Sarah Morrow, MD, MS, FRCPC, FAAN | CMSC 2020 MS Academy

Neurology Academy

ChariotMS: the first DMT trial in advanced multiple sclerosis

MS Drug Safety (COVID-19/coronavirus) Analysis by Experts (Giovannoni, Waubant)

Dr. Brandon Beaber

Dr Wallace Brownlee - Real life data on newer drugs in MS

At the Limits - Leading Medical Education

Dr John Corboy on Research About Stopping DMTs for MS

MS Variance – Rachel Dorsey-Campbell: DMT Monitoring

Neurology Academy

Dr Patricia Coyle on Considerations in Choosing a DMT for MS

MS Intermediate MasterClass - Margaret Solomons - Project finalist

Neurology Academy

Aksel Siva, EAN 2019 – Treatment strategies in multiple sclerosis

Touch Medical Media